Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the 'DR-Pro-DEX Study'

Acta Diabetologica
Matias IglickiA Loewenstein

Abstract

Intravitreal anti-vascular endothelial growth factor agents have been shown to reduce diabetic retinopathy (DR) progression; data on the effects of intravitreal corticosteroids on modifying disease severity are limited. This study evaluates the long-term effect of intravitreal dexamethasone implant (DEX) on the severity and progression of non-proliferative DR (NPDR). This was a retrospective cohort study. Sixty eyes from 60 consecutive patients with NPDR and diabetic macular edema (DME) treated with dexamethasone implant (DEX group) and 49 eyes from consecutive 49 patients without DME requiring observation only. Fundus angiography images from baseline and after 24 months were graded by two masked assessors into mild, moderate and severe NPDR and PDR, according to the ETDRS classification. Patients were followed up 1-3 and 4-6 months after each DEX implant. Re-treatment with DEX implant was on a pro re nata basis. Records were reviewed for performance of panretinal photocoagulation. Main outcome was as follows: change of DR ≥ 1 grade and progression to proliferative diabetic retinopathy (PDR). Three eyes (5%) in the DEX group and 43 (87.8%) eyes in the control group progressed to PDR (P < 0.0001). Twenty-five eyes (41.7%) in the...Continue Reading

References

Nov 1, 1995·Archives of Ophthalmology·R KleinB E Klein
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jun 15, 1996·The Journal of Clinical Investigation·M MizutaniM Lorenzi
Jul 20, 2004·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Hideharu FunatsuSadao Hori
Mar 26, 2005·Investigative Ophthalmology & Visual Science·Hiroshi TamuraNagahisa Yoshimura
Apr 11, 2006·British Journal of Pharmacology·Peter J Barnes
Jun 4, 2011·Progress in Retinal and Eye Research·Johnny Tang, Timothy S Kern
Feb 15, 2012·Ophthalmology·Quan Dong NguyenUNKNOWN RISE and RIDE Research Group
Sep 12, 2012·Archives of Ophthalmology·Michael S IpJason S Ehrlich
May 22, 2013·Diabetologia·H C LookerUNKNOWN Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative
Jun 29, 2013·JAMA Ophthalmology·Susan B BresslerUNKNOWN Diabetic Retinopathy Clinical Research Network
Jun 2, 2014·Acta Diabetologica·David RooneyCharumathi Sabanayagam
Mar 13, 2017·Ophthalmology·Michael S IpJason S Ehrlich
Apr 28, 2017·JAMA Ophthalmology·Susan B BresslerUNKNOWN Diabetic Retinopathy Clinical Research Network
May 17, 2017·Investigative Ophthalmology & Visual Science·Stela Vujosevic, Rafael Simó

❮ Previous
Next ❯

Citations

May 16, 2019·Acta Diabetologica·Matias IglickiUNKNOWN International Retina Group (IRG)
Apr 14, 2020·Journal of Ophthalmology·Mojca UrbančičAlenka Lavrič
Apr 29, 2020·Journal of Drug Assessment·María Del Pino Cidad-BetegónGema Casado-Abad
May 19, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Yue ZhaoXiaofei An
Apr 14, 2021·International Journal of Retina and Vitreous·David S BoyerQuan Dong Nguyen
Apr 27, 2021·Expert Opinion on Biological Therapy·Lorenzo Ferro DesideriMassimo Nicolò
Jul 16, 2021·Therapeutic Advances in Ophthalmology·Avadhesh Oli, Divya Balakrishnan
Apr 7, 2020·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Massimo NicolòCarlo Enrico Traverso
May 3, 2019·Ophthalmic Research·Dinah ZurAnat Loewenstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.